DVA February 2026 Options Begin Trading

DaVita (DVA) is the subject of two options strategies: a sell-to-open $115 put (bid $3.00) implies a net cost basis of $112.00 versus the current price of $117.29, is ~2% out-of-the-money and carries a modeled 62% chance to expire worthless, equating to a 2.61% return on cash or 14.88% annualized. The covered-call example uses a $120 strike (bid $4.20) which is ~2% OTM and carries a 50% chance to expire worthless; if called, the total return to the seller would be 5.89% to February 2026 (3.58% immediate yield boost, 20.42% annualized). Implied volatilities are ~34% (put) and 32% (call) versus a trailing 12‑month volatility of 31%; Stock Options Channel will track odds and contract histories on its site.

Analysis

Market structure: Short-dated income strategies (put-sellers and covered-call writers) are the primary beneficiaries — selling the DVA Feb-2026 $115 put collects $3 (net entry $112) with a quoted 62% chance of expiring worthless, and the $120 call yields $4.20 (5.89% capped return). Dealers and brokers capture commissions and gamma exposure; large-scale put-writing increases latent buy-side demand (assignment risk) and can mechanically support the equity around strikes. Cross-asset impact is muted but concentrated options flows can transiently compress equity liquidity and reverberate into single-name CDS spreads and healthcare sector ETFs.

Risk assessment: Key tail risks are regulatory/reimbursement changes from CMS (single-event shock >20% move), major litigation, or systemic macro drawdowns that spike IV from ~34% to >60%. Timing matters: immediate (days) — theta decay wins for sellers; short-term (weeks–months) — IV shifts around earnings/CMS guidance; long-term (quarters) — fundamental revenue/margin impact from reimbursement. Hidden risks include assignment funding strain, concentrated open interest at 115/120 strikes and broker margin/early assignment conventions.

Trade implications: Actionable plays — (A) Sell-to-open DVA Feb-2026 115 puts size to risk 1–3% of portfolio notional, limit premium >= $3, buy 105 puts to form a 115/105 bull-put spread if unwilling to take assignment; set buy-back if DVA < $105 or IV > 60%. (B) For equity holders, buy DVA up to $117.50 and sell Feb-2026 $120 covered calls for >= $4.20 to harvest ~5.9% to upside through Feb; use collars (buy 100-110 puts) if regulatory risk is priced in. Consider long DVA / short FMS to isolate US reimbursement upside vs EU exposure.

Contrarian angles: The market understates CMS tail risk — historical parallels (2019 CMS proposals) produced 20–30% moves in dialysis stocks, so selling naked premium is only prudent if you size for that. IV is only ~3 p.p. above realized (34% vs 31%), so premium is not rich — selling premium is underpriced for true regulatory-event risk. Widespread covered-call selling could artificially cap upside and increase likelihood of assignment, creating a momentum reversal if a positive catalyst appears.

Key Decisions for Investors

• Sell-to-open DVA Feb-2026 $115 puts (1 contract per $11.5k notional) to collect >= $3 premium — size total exposure to 1–3% of portfolio and hedge with buying the $105 put to create a 115/105 bull-put spread if you want defined risk; unwind if DVA < $105 or IV spikes above 60%.
• Establish a covered-call income position: buy DVA up to $117.50 and sell Feb-2026 $120 calls for >= $4.20 to lock ~5.9% return to expiry; if concerned about CMS/regulatory risk, implement a collar by buying Feb-2026 $100–$110 puts (pay up to $2.00) to cap downside to ~8–12%.
• Relative-value pair: go long DVA and short Fresenius Medical Care (FMS) sized 1:1 by market cap exposure to isolate U.S. reimbursement upside — enter on dips; target 6–12 month horizon and trim when spread narrows by 50% or DVA outperforms by >15%.
• Monitor two specific catalysts over next 90 days: any CMS notices/proposals and DVA quarterly results; if CMS issues unfavorable guidance or DVA misses revenue/EBITDA targets by >5%, close premium-selling positions and buy downside protection (long puts) immediately.